UBS Group AG Acquires 257,947 Shares of Adaptive Biotechnologies Corporation $ADPT

UBS Group AG grew its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 101.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 511,927 shares of the company’s stock after purchasing an additional 257,947 shares during the period. UBS Group AG’s holdings in Adaptive Biotechnologies were worth $8,314,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ADPT. Ameriprise Financial Inc. raised its stake in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after acquiring an additional 2,062,282 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Adaptive Biotechnologies during the third quarter valued at $14,934,000. First Trust Advisors LP raised its stake in shares of Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after acquiring an additional 726,184 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its position in shares of Adaptive Biotechnologies by 161.1% during the third quarter. Qube Research & Technologies Ltd now owns 952,229 shares of the company’s stock worth $14,245,000 after buying an additional 587,461 shares during the period. Institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 19,037 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $14.23, for a total value of $270,896.51. Following the completion of the sale, the chief operating officer directly owned 377,802 shares in the company, valued at approximately $5,376,122.46. This trade represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 37,263 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total transaction of $566,024.97. Following the completion of the sale, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at $33,122,068.42. The trade was a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,417,168 shares of company stock valued at $34,153,000 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $12.83 on Monday. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -38.88 and a beta of 2.16. The firm has a fifty day simple moving average of $13.93 and a two-hundred day simple moving average of $15.73. Adaptive Biotechnologies Corporation has a 12 month low of $8.50 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the company posted ($0.20) earnings per share. Equities analysts predict that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.